Jay H. Jacobs, M.D., F.A.C.C.
Expertise: Invasive Non-Interventional Cardiology and Echocardiology
Dr. Jay H. Jacobs is Board Certified in Cardiovascular Diseases and Internal Medicine. He completed his Fellowship in Cardiology at the Newark Beth Israel Medical Center after completing his Residency in Internal Medicine through the Affiliated Hospitals Program, College of Medicine of New Jersey. Dr. Jacobs earned a Bachelor of Science in Electrical Engineering from Ohio University.
Research:
2000: SPORTIF V -An Efficacy and Safety Study ofthe Oral 2000 Direct Thrombin Inhibitor H 376/95 Compared with Dose-Adjusted Warfarin (Coumadin®) in the Prevention of Stroke and Systemic Embolic Events in patients with Atrial Fibrillation. Sub-Investigator
1999: GUSTO IV AMI Trial-A Phase III Randomized, Open-Label Trial Evaluating The Efficacy And Safety Of ReoPro7 (Abciximab) In Combination With Reduced Dose Retavase7/RapilysinJ (Recombinant Plasminogen Activator, Reteplase, r-PA) For The Treatment Of Acute Myocardial Infarction. Sub-Investigator.
1999: VALIANT Trial -Valsartan In Acute Myocardial Infarction Trial. A multinational, , double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with valsartan, captopril and their combination in high risk patients after myocardial infarction. Sponsored by Novartis Pharmaceuticals Corporation. Sub-Investigator.
